2026-04-29T12:22:45Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/65162024-09-27T09:24:55Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Halcox, Julian P. J. author Roy, Carine author Tubach, Florence author Banegas, José Ramón author Dallongeville, Jean author De Backer, Guy author Guallar, Eliseo author Sazova, Oguen author Medina, Jesus author Perk, Joep author Steg, Philippe Gabriel author Rodríguez-Artalejo, Fernando author Borghi, Claudio author 2014 Background: Elevated C-reactive protein (CRP) levels are associated with high cardiovascular risk, and might identify patients who could benefit from more carefully adapted risk factor management. We have assessed the prevalence of elevated CRP levels in patients with one or more traditional cardiovascular risk factors. Methods: Data were analysed from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA, ClinicalTrials. gov Identifier: NCT00882336), which included patients (aged = 50 years) from 12 European countries with at least one traditional cardiovascular risk factor but no history of cardiovascular disease. Analysis was also carried out on the subset of patients without diabetes mellitus who were not receiving statin therapy. Results: In the overall population, CRP levels were positively correlated with body mass index and glycated haemoglobin levels, and were negatively correlated with high- density lipoprotein cholesterol levels. CRP levels were also higher in women, those at higher traditionally estimated cardiovascular risk and those with greater numbers of metabolic syndrome markers. Among patients without diabetes mellitus who were not receiving statin therapy, approximately 30\% had CRP levels >= 3 mg/ L, and approximately 50\% had CRP levels = 2 mg/ L, including those at intermediate levels of traditionally estimated cardiovascular risk. Conclusions: CRP levels are elevated in a large proportion of patients with at least one cardiovascular risk factor, without diabetes mellitus who are not receiving statin therapy, suggesting a higher level of cardiovascular risk than predicted according to conventional risk estimation systems. BMC Cardiovasc Disord. 2014; 14(1):25 10.1186/1471-2261-14-25 1471-2261 BMC Cardiovascular Disorders 24564178 http://hdl.handle.net/20.500.12105/6516 C-reactive protein Cardiovascular disease Epidemiology Risk factors/global assessment CORONARY-HEART-DISEASE PRIMARY PREVENTION CLINICAL-PRACTICE HEALTHY-ADULTS PREDICTION WOMEN INFLAMMATION POPULATION MORTALITY JUPITER C-reactive protein levels in patients at cardiovascular risk: EURIKA study